rosuvastatin + ranitidine

This is a combination of two small molecule drugs, rosuvastatin and ranitidine. Rosuvastatin is a synthetic HMG-CoA reductase inhibitor (statin) used to lower cholesterol and reduce the risk of cardiovascular disease by inhibiting the enzyme responsible for cholesterol synthesis in the liver, leading to decreased LDL cholesterol and triglycerides, and increased HDL cholesterol. Ranitidine is a histamine H2 receptor antagonist that reduces stomach acid production by blocking histamine at H2 receptors of gastric parietal cells; it is primarily used for conditions like peptic ulcer disease, gastroesophageal reflux disease (GERD), and other disorders involving excessive gastric acid secretion. There are no known approved fixed-dose combination products containing both agents; however, they may be co-administered in clinical practice. Notably, co-administration can increase serum concentrations of rosuvastatin due to pharmacokinetic interactions with ranitidine[5]. Both drugs have been associated with safety concerns—rosuvastatin with myopathy/rhabdomyolysis risk at high doses or when combined with certain other medications[3], and ranitidine due to potential contamination with nitrosamines (possible carcinogens)[6].